Academic Journal
Q1Signal Transduction and Targeted Therapy
About Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy is a scholarly journal published by Springer Nature. SCImago 2025 places it in Q1 with an SJR of 17.74 and an H-index of 224.
Its listed coverage is 2016-2026 and its research categories include Cancer Research (Q1); Genetics (Q1). The 2025 dataset reports 423 documents and 58350 citations across the latest three-year reporting window.
Signal transduction and targeted therapy are revolutionizing the field of cancer treatment and other chronic diseases by offering a more precise and effective approach. Unlike traditional therapies, which often affect both healthy and diseased cells, targeted therapies interfere with specific molecular targets involved in disease progression. At the heart of these therapies lies the complex process of signal transduction—the method by which cells respond to external signals.
What is Signal Transduction?
Signal transduction is a series of biochemical processes through which a cell converts an external signal into a functional change. This process begins when signaling molecules, such as hormones or growth factors, bind to specific receptors on the cell surface. These receptors then activate a cascade of intracellular signals, often involving kinases, enzymes, or secondary messengers, which ultimately lead to cellular responses like growth, division, differentiation, or apoptosis.
Aberrations in signal transduction pathways can lead to uncontrolled cell growth and cancer. For instance, mutations in genes encoding growth factor receptors or downstream signaling molecules can cause constant activation of these pathways, even in the absence of external signals.
Targeted Therapy: Precision Treatment
Targeted therapy aims to block these abnormal signaling pathways that drive disease. Unlike chemotherapy, which affects rapidly dividing cells indiscriminately, targeted therapy is designed to interfere with specific molecules necessary for tumor growth and survival.
Some common targets include:
-
EGFR (Epidermal Growth Factor Receptor): Overexpressed in several cancers, including lung and colorectal cancer.
-
HER2 (Human Epidermal Growth Factor Receptor 2): A key target in breast cancer.
-
BRAF and MEK proteins: Often mutated in melanoma.
-
VEGF (Vascular Endothelial Growth Factor): Involved in the formation of new blood vessels (angiogenesis) that support tumor growth.
By inhibiting these pathways, targeted therapies can slow or stop disease progression with fewer side effects compared to conventional treatments.
Types of Targeted Therapies
-
Monoclonal Antibodies – Engineered proteins that bind to specific antigens on the surface of cancer cells, blocking growth signals or marking cells for immune destruction.
-
Small Molecule Inhibitors – These penetrate the cell and block enzymes or proteins involved in signal transduction, such as tyrosine kinase inhibitors (TKIs).
-
Hormone Therapies – Target hormone-sensitive cancers like breast and prostate cancer by interfering with hormone signaling pathways.
Benefits and Limitations
Targeted therapy has shown great promise in improving survival rates and quality of life. However, not all patients respond equally, and resistance can develop over time. Therefore, biomarker testing and personalized medicine are crucial for selecting the right therapy for each individual.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Signal transduction and targeted therapy are rapidly evolving fields in biomedical research and clinical medicine, with significant implications for disease treatment, especially in oncology. These approaches focus on understanding and intervening in the cellular communication pathways that regulate growth, survival, and differentiation, offering new hope for more precise and effective treatments.
What is Signal Transduction?
Signal transduction refers to the process by which cells respond to external stimuli through a series of molecular events, typically involving protein interactions and phosphorylation cascades. These pathways transmit signals from the cell surface to the nucleus, resulting in changes in gene expression and cellular behavior. Dysregulation of these pathways is a hallmark of many diseases, including cancer, autoimmune disorders, and neurodegenerative conditions.
Common signal transduction pathways include the MAPK/ERK, PI3K/AKT, and JAK/STAT pathways. Aberrant activation of these signaling networks can lead to uncontrolled cell proliferation and survival, making them critical targets for therapeutic intervention.
Rise of Targeted Therapy in Modern Medicine
Targeted therapy is a form of precision medicine that specifically inhibits molecules involved in signal transduction pathways driving disease progression. Unlike traditional chemotherapy, which affects both healthy and cancerous cells, targeted therapies are designed to interfere with specific molecular targets, reducing side effects and improving outcomes.
For example, tyrosine kinase inhibitors (TKIs) like imatinib have revolutionized the treatment of chronic myeloid leukemia by blocking the BCR-ABL fusion protein. Similarly, HER2 inhibitors such as trastuzumab are effective in HER2-positive breast cancer by targeting the HER2 receptor involved in cell signaling.
Expanding Applications Beyond Cancer
While targeted therapy is most commonly associated with cancer treatment, its scope is expanding. Researchers are exploring targeted approaches for inflammatory diseases, cardiovascular conditions, and even rare genetic disorders. Drugs that inhibit Janus kinases (JAKs) have shown promise in treating rheumatoid arthritis and other autoimmune diseases by modulating cytokine signaling.
Furthermore, combining targeted therapies with immunotherapies, such as checkpoint inhibitors, is opening new avenues in cancer treatment, enhancing the immune system’s ability to recognize and destroy tumor cells.
Challenges and Future Directions
Despite the promise, challenges remain in signal transduction and targeted therapy. Drug resistance, tumor heterogeneity, and the complexity of signaling networks can limit long-term efficacy. However, advancements in genomics, proteomics, and bioinformatics are enabling better identification of therapeutic targets and biomarkers, allowing for more personalized treatment strategies.
Emerging technologies like CRISPR gene editing, nanotechnology, and AI-driven drug discovery are also playing a crucial role in accelerating the development of next-generation targeted therapies.
Recent Research Articles
Latest publications matched automatically by ISSN.
Precision tuning of STING signaling: a mutational blueprint
Angelica Cuapio, Hans-Gustaf Ljunggren
2026-09-09 · DOI: 10.1038/s41392-026-02968-yHighly efficient intranasal H5N1 vaccine based on a safe vesicular stomatitis virus (VSV) vector
Ziteng Liang, Mengyi Zhang, Jie Zhang, Hongyu Chen et al.
2026-09-09 · DOI: 10.1038/s41392-026-02933-9Disulfidptosis: molecular mechanisms and therapeutic targets
Cong Wang, Jialin Zhou, Binghui Jin, Guangyao Li et al.
2026-09-08 · DOI: 10.1038/s41392-026-03001-yReceptor-defined targeting of a genomically unique melanoma-enriched noncanonical antigen
Thomas Morgan Hulen, Michael Douglas Crowther, Luke Alexander Schuster, Shawez Khan et al.
2026-09-08 · DOI: 10.1038/s41392-026-02961-5Myeloid-derived suppressor cells in cancer: biology, regulatory networks and theranostic prospects
Rongjun Deng, Xiuyun Bai, Jue Yang, Wanting Ye et al.
2026-09-08 · DOI: 10.1038/s41392-026-02998-6B cells in cancer: functions, mechanisms and therapeutic advances
Hao Zhang, Kun Cheng, Ji Mo, Mingrui Chen et al.
2026-09-08 · DOI: 10.1038/s41392-026-02811-4Nucleic acid aptamers: new methods for selection, target validation, molecular diagnostics and therapeutics
Ding-Kun Ji, Haozhi Lei, Jia Liu, Fangfang Xia et al.
2026-09-07 · DOI: 10.1038/s41392-026-02930-ySleep duration links to biological aging clocks: when sleep gets tough, aging gets going
Despina Tawadros, Melek Canan Arkan
2026-09-07 · DOI: 10.1038/s41392-026-02997-7Dynamics of neutralizing antibody responses after trivalent XBB.1.5 booster vaccination: a 480-day longitudinal study
Meng-Fei Wang, Guo-Ping Cao, Guo-Jian Yang, Xue-Dong Song et al.
2026-09-07 · DOI: 10.1038/s41392-026-02949-1Correction: Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects
Xiaojun Wang, Hui Ding, Zongyang Li, Yaonan Peng et al.
2026-09-05 · DOI: 10.1038/s41392-026-02976-yItaconate and its derivatives in human health and diseases
Jianyou Gu, Wenying Zhang, Junfeng Zhang, Silue Zeng et al.
2026-09-04 · DOI: 10.1038/s41392-026-02936-6Infection and α-ketoglutarate/oxygen inhibition converge to CDC20 to promote cancer cell aneuploidy
Yi-Neng Zhou, Fu-Jiang Xu, Cui-Fang Yao, Yang Li et al.
2026-09-04 · DOI: 10.1038/s41392-026-02956-2T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy
Lauren van den Broecke, Arne Van der Vreken, Fenja Watté, Fien Meeus et al.
2026-09-03 · DOI: 10.1038/s41392-026-02923-xCDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism
Ilenia Pellarin, Valentina Rossi, Riccardo Giuseppe Margiotta, Javad Karimbayli et al.
2026-09-03 · DOI: 10.1038/s41392-026-02932-wImmune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential
Minmin Xiang, Shuang Liu, Desheng Xiao, Yongguang Tao et al.
2026-09-02 · DOI: 10.1038/s41392-026-02810-5miRNAs as cell-intrinsic epigenetic regulators in muscle in type 2 diabetes
Allah Nawaz, Marsel Lino, Nida Haider, Antonio S. Gomes et al.
2026-09-02 · DOI: 10.1038/s41392-026-02846-7Intratumoral Mycobacterium abscessus promotes cytidine deaminase mutagenesis in non-small cell lung cancer
Xun Li, Mei-Ting Li, Ke-Peng Ou, Pan-Qi Gao et al.
2026-09-01 · DOI: 10.1038/s41392-026-02878-zPrecision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation
Zicheng Deng, Wen Gao, Jonathan Do, Shravya Aragam et al.
2026-09-01 · DOI: 10.1038/s41392-026-02982-0Regulatory T cell induction strategies and applications in the treatment of immune and non-immune diseases
Yaqi Chen, Yingying Shi, Jian You
2026-09-01 · DOI: 10.1038/s41392-026-02910-2First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial
Yue Liu, Yanqiao Zhang, Rongbo Lin, Xiaobing Chen et al.
2026-09-01 · DOI: 10.1038/s41392-026-02938-4Reviews
Community Reviews
Version History
April 13, 2025 at 12:12 pm
April 13, 2025